Claims for Patent: 11,975,012

Summary for Patent: 11,975,012

Title:	Remdesivir treatment methods
Abstract:	Provided herein are methods of treating or preventing a viral infection in a subject comprising administering a compound of Formula I, Formula Ia, or Formula Ib, or a pharmaceutically acceptable salt thereof, wherein the subject is not being treated with chloroquine, or an analog or salt thereof.
Inventor(s):	Tomas Cihlar
Assignee:	Gilead Sciences Inc
Application Number:	US17/333,389
Patent Litigation and PTAB cases:	See patent lawsuits and PTAB cases for patent 11,975,012
Patent Claims:	1. A method of treating a viral infection in a human in need thereof, the method comprising administering to the human a therapeutically effective amount of a compound of Formula I, Formula Ia, or Formula Ib, or a pharmaceutically acceptable salt thereof: wherein the human is not being treated with chloroquine, or an analog or salt thereof, thereby treating the viral infection. 2. The method of claim 1, wherein the human has not been administered chloroquine, or an analog or salt thereof, within 1 day of receiving a first dose of the compound of Formula I, Formula Ia, or Formula Ib, or pharmaceutically acceptable salt thereof. 3. The method of claim 2, wherein the human has not been administered chloroquine, or an analog or salt thereof, within 10 days of receiving the first dose of the compound of Formula I, Formula Ia, or Formula Ib, or pharmaceutically acceptable salt thereof. 4. The method of claim 1, further comprising instructing the human not to take chloroquine, or an analog or salt thereof, during the treatment of the viral infection. 5. The method of claim 1, wherein the human is not administered chloroquine, or an analog or salt thereof, during the treatment of the viral infection. 6. The method of claim 1, wherein the human has a plasma or blood concentration of the chloroquine, or an analog or salt thereof, of less than 50 ng/mL, at the time a first dose of the compound of Formula I, Formula Ia, or Formula Ib, or pharmaceutically acceptable salt thereof, is administered to the human. 7. The method of claim 1, wherein the chloroquine, or an analog or salt thereof, is chloroquine, desethylchloroquine, hydroxychloroquine, desethylhydroxychloroquine, or bisdesethylhydroxychloroquine, or a pharmaceutically acceptable salt thereof. 8. The method of claim 7, wherein the chloroquine, or an analog or salt thereof, is chloroquine, or a pharmaceutically acceptable salt thereof. 9. The method of claim 7, wherein the chloroquine, or an analog or salt thereof, is hydroxychloroquine, or a pharmaceutically acceptable salt thereof. 10. The method of claim 1, comprising administering to the human the therapeutically effective amount of the compound of Formula I, or a pharmaceutically acceptable salt thereof: 11. The method of claim 1, wherein the compound of Formula I, Formula Ia, or Formula Ib, or a pharmaceutically acceptable salt thereof, is administered intravenously. 12. The method of claim 1, wherein the human weighs at least 40 kg, and the compound of Formula I, Formula Ia, or Formula Ib, or a pharmaceutically acceptable salt thereof, is administered intravenously in the first dose of 200 mg on day 1, and administered intravenously in a second dose of 100 mg on each of the following 4 days. 13. The method of claim 12, wherein the second dose of 100 mg is administered for an additional 1 to 5 days. 14. The method of claim 1, wherein the human weighs from 3.5 kg to less than 40 kg, and the compound of Formula I, Formula Ia, or Formula Ib, or a pharmaceutically acceptable salt thereof, is administered intravenously in the first dose of 5 mg/kg on day 1, and administered intravenously in a second dose of 2.5 mg/kg on each of the following 4 days. 15. The method of claim 1, wherein the viral infection is caused by an Arenaviridae virus. 16. The method of claim 1, wherein the viral infection is caused by a Coronaviridae virus. 17. The method of claim 16, wherein the Coronaviridae virus is SARS virus, SARS-CoV-2 virus, MERS virus, 229E virus, NL63 virus, OC43 virus, or HKU1 virus. 18. The method of claim 16, wherein the Coronaviridae virus is SARS-CoV-2. 19. The method of claim 16, wherein the viral infection is caused by a virus having at least 70% sequence homology to a viral polymerase selected from the group consisting of SARS-CoV polymerase, SARS-CoV-2 polymerase, and MERS polymerase. 20. The method of claim 1, wherein the viral infection is caused by a Filoviridae virus. 21. The method of claim 20, wherein the Filoviridae virus is Ebola or Marburg. 22. The method of claim 1, wherein the viral infection is caused by a Flaviviridae virus. 23. The method of claim 1, wherein the viral infection is caused by a Pneumoviridae virus. 24. The method of claim 23, wherein the Pneumoviridae virus is respiratory syncytial virus or human metapneumovirus. 25. The method of claim 1, wherein the viral infection is caused by a Paramyxoviridae virus. 26. The method of claim 25, wherein the Paramyxoviridae virus is Nipah or parainfluenza virus. 27. A method of optimizing concentration of a compound of Formula II, or a pharmaceutically acceptable salt thereof, in plasma or blood of a human: the method comprising administering to the human an antiviral compound; wherein the human has not been administered chloroquine, or an analog or salt thereof; the antiviral compound is converted to a compound of Formula II, or a pharmaceutically acceptable salt thereof upon administration to the human; and the concentration of the compound of Formula II in plasma or blood is optimized in the absence of chloroquine, or an analog or salt thereof. 28. The method of claim 27, wherein the human has not been administered chloroquine, or an analog thereof, within 1 day prior to the treatment of the viral infection. 29. The method of claim 27, wherein the human has not been administered chloroquine, or an analog thereof, within 10 days prior to the treatment of the viral infection. 30. The method of claim 27, wherein the human has a plasma or blood concentration of the chloroquine, or an analog or salt thereof, of less than 50 ng/mL, at the time a first dose of the antiviral compound is administered to the human. 31. The method of claim 27, wherein the plasma or blood concentration of the compound of Formula II in the human is higher than a second concentration of a compound of Formula II in a reference human treated with chloroquine, or an analog or salt thereof. 32. The method of claim 27, wherein the antiviral compound is a compound of Formula I, Formula Ia, or Formula Ib, or a pharmaceutically acceptable salt thereof, 33. A method of determining a delivery dose of a compound of Formula I, Formula Ia, or Formula Ib, or a pharmaceutically acceptable salt thereof, for treating a viral infection in a human in need thereof, the method comprising: (a) providing an original dose of the compound of Formula I, Formula Ia, or Formula Ib, or a pharmaceutically acceptable salt thereof; (b) determining whether the human has been administered chloroquine, or an analog or salt thereof; and (c1) if the human has been administered chloroquine, or an analog or salt thereof, increasing the original dose of the compound of Formula I, Formula Ia, or Formula Ib, or a pharmaceutically acceptable salt thereof, to determine the delivery dose, or (c2) if the human has not been administered chloroquine, or an analog or salt thereof, selecting the original dose of the compound of Formula I, Formula Ia, or Formula Ib, or a pharmaceutically acceptable salt thereof, as the delivery dose. 34. A method of forming an optimized amount of a compound of Formula II in a human in need thereof, comprising administering to the human a therapeutically effective amount of a compound of Formula Ia, and instructing the human not to take chloroquine, or an analog or salt thereof, wherein upon administration to the human, the compound of Formula Ia is metabolized to the compound of Formula II, wherein the compound of Formula II has the structure: and wherein the compound of Formula Ia has the structure: 35. A method of reducing the risk of decreased efficacy of the compound of Formula Ia, or a pharmaceutically acceptable salt thereof, in a human suffering from a viral infection the method comprising: (a) determining if the human has taken chloroquine, or an analog or salt thereof, prior to administration of the compound of Formula Ia, or a pharmaceutically acceptable salt thereof; (b) instructing the human not to take chloroquine, or an analog or salt thereof, while being treated with the compound of Formula Ia, or a pharmaceutically acceptable salt thereof; and (c) administering the compound of Formula Ia, or a pharmaceutically acceptable salt thereof, to the human, thereby reducing the risk of decreased efficacy of the compound of Formula Ia, or a pharmaceutically acceptable salt thereof. 36. A method of preventing a contraindication in a human suffering from a viral infection, the method comprising: (a) determining if the human has taken chloroquine, or an analog or salt thereof, prior to administration of the compound of Formula Ia, or a pharmaceutically acceptable salt thereof, (b) instructing the human not to take chloroquine, or an analog or salt thereof, while being treated with the compound of Formula Ia, or a pharmaceutically acceptable salt thereof; and (c) administering the compound of Formula Ia, or a pharmaceutically acceptable salt thereof, to the human, thereby preventing a contraindication in the human. 37. A method of maintaining optimized efficacy of a compound of Formula Ia, or a pharmaceutically acceptable salt thereof, in a human suffering from a viral infection, the method comprising: (a) determining if the human has taken chloroquine, or an analog or salt thereof, prior to administration of the compound of Formula Ia, or a pharmaceutically acceptable salt thereof; (b) instructing the human not to take chloroquine, or an analog or salt thereof, while being treated with the compound of Formula Ia, or a pharmaceutically acceptable salt thereof; and (c) administering the compound of Formula Ia, or a pharmaceutically acceptable salt thereof, to the human, thereby maintaining efficacy of the compound of Formula Ia, or a pharmaceutically acceptable salt thereof. 38. A method of reducing the risk of a reduced plasma concentration of a compound of Formula II, in a human suffering from a viral infection, the method comprising: (a) determining if the human has taken chloroquine, or an analog or salt thereof, prior to administration of a compound of Formula Ia, or a pharmaceutically acceptable salt thereof; (b) instructing the human not to take chloroquine, or an analog or salt thereof, while being treated with the compound of Formula Ia, or a pharmaceutically acceptable salt thereof; and (c) administering the compound of Formula Ia, or a pharmaceutically acceptable salt thereof, to the human, thereby reducing the risk of a reduced plasma concentration of the compound of Formula II.